N2OFF loans $250K to MitoCareX, pending acquisition funding

Nexentis Technologies Inc.

$250,000 loan to MitoCareX Bio Ltd., 6-month term, interest at Israel tax rate + 3%.
Loan guaranteed by L.I.A. Pure Capital Ltd.
Second $250K loan to MitoCareX; prior loan dated Dec 22, 2024.
Loan intended to cover MitoCareX costs until closing of Feb 2025 acquisition agreement.
If acquisition closes, outstanding loan amount deducted from first-year allocation to MitoCareX.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.